Orega Biotech
Location: France, office address not availableorega-biotech.com
OREGA Biotech discovers and develops first-in-class monoclonal antibodies for cancer immunotherapy. IPH5201 (anti-CD39) is in Phase 2 in early-stage NSCLC.
Founders and contacts
- FoundersBeing confirmed, locked
- Founder emailsBeing confirmed, locked
- LinkedInCompany page, locked
Explore
More startups in France
Is Orega Biotech yours? Feature it on the map for $49 a month, in front of everyone who opens it.
Are you a founder of Orega Biotech and want your details removed? Write to us and we remove them within 72 hours.